Antimicrobial Catheter Lock Solution
TauroLock™ is approved to be instilled into catheter-based devices for central venous access in order to prevent CRBSI and biofilm formation. TauroLock™ maintains patency without undesired side-effects.
TauroLock™ contains anticoagulant and antimicrobial substances. Active ingredients in TauroLock™ are (cyclo)-taurolidine and citrate (4%). Other components include water for injection. The product is sterile filter processed and supplied as a clear, sterile, non-pyrogenic solution. It is to be used with a port or a catheter-based vascular access device. It is to be instilled in the device lumens between treatments in order to make the internal flow passages resistant to clot formation and hostile to bacterial and fungal growth.
TauroLock™ is to be instilled into the device lumen between treatments. The solution must be withdrawn prior to initiating the next treatment. If aspiration of TauroLock™ is not needed or not possible, slow flushing of TauroLock™ prior to the next treatment does not cause systemic effects.
Antimicrobial Catheter Lock Solution
Taurolock™-HEP500 is approved to be instilled into catheter-based devices for central venous access in order to prevent CRBSI and bio-film formation. Taurolock™-HEP500 maintains patency without undesired side-effects.
TauroLock™-Hep500 contains anticoagulant and antimicrobial substances. Active ingredients in TauroLock™-Hep500 are (cyclo)-taurolidine, citrate (4%) and heparin (500 IU/mL). Other components include water for injection. The product is sterile filter processed and supplied as a clear, sterile, non-pyrogenic solution. It is to be used with a port or a catheter-based vascular access device. It is to be instilled in the device lumens between treatments in order to make the internal flow passages resistant to clot formation and hostile to bacterial and fungal growth.
TauroLock™-Hep500 is to be instilled into the device lumen between treatments. The solution must be withdrawn prior to initiating the next treatment.
Antimicrobial Catheter Lock Solution
Taurolock™-U25.000 is approved to be instilled into catheter-based devices for central venous access in order to prevent CRBSI and bio-film formation. Taurolock™-U25.000 maintains patency without undesired side-effects.
TauroLock™-U25.000 contains substances to ensure patency and provide infection control in the device. Active ingredients in TauroLock™-U25.000 are (cyclo)-taurolidine, citrate (4%) and urokinase (25.000 IU). Other components include water for injection. The product is sterile filter processed and supplied as a clear, sterile, non-pyrogenic solution. Urokinase is delivered in a separate vial and is reconstituted with the contents of the ampoule just before use. Each single-use ampoule contains 5 mL. It is to be used with a port or a catheter-based vascular access device. TauroLock™-U25.000 is instilled into the device lumen between treatments in order to make the internal flow passages resistant to clot formation and hostile to bacterial and fungal growth.
Taurolock™-U25.000 is to be instilled into the device lumen between treatments. The solution must be withdrawn prior to initiating the next treatment.
